Sign inJoin waitlistJoin the waitlist

Sharad Khurana

Assistant Professor, Medicine · University of Arizona College of Medicine-Tucson

Credentials: · · · · · · · ·

History

University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present
University of Arizona College of Medicine-Tucson
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2017–2020
Internal Medicine
John H. Stroger Jr. Hospital of Cook County
2014–2017
Rush University Medical Center
2017
Grant Medical College, Mumbai
2009–2013

Research

Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Systematic review or meta-analysis · Transplantation and Cellular Therapy · 2021 · 41 citations
Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis
Systematic review or meta-analysis · Transplant Infectious Disease · 2022 · 38 citations
Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report
Case report · Melanoma Research · 2019 · First of 3 authors · 11 citations

LJ
Liuyan Jiang
5 papers
Muhammad Husnain
5 papers
James Foran
4 papers
Emmanuel Katsanis
3 papers
Joseph McGuirk
3 papers
MM
Megan Melody
3 papers · 3 as a resident
Moazzam Shahzad
3 papers · 3 as a fellow
Muhammad Mushtaq
3 papers · 1 as a fellow
NA
Nausheen Ahmed
3 papers
Peiman Hematti
3 papers
SC
Sibgha Chaudhary
3 papers · 2 as a resident
Sunil Abhyankar
3 papers

Clinical trials

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027